We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita HealthCare (DVA) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
DaVita HealthCare (DVA - Free Report) ended the recent trading session at $139.43, demonstrating a -1.23% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.14%. On the other hand, the Dow registered a loss of 0.04%, and the technology-centric Nasdaq increased by 0.38%.
Prior to today's trading, shares of the kidney dialysis provider had gained 3.08% outpaced the Medical sector's loss of 1.94% and lagged the S&P 500's gain of 5.35%.
The investment community will be paying close attention to the earnings performance of DaVita HealthCare in its upcoming release. The company is slated to reveal its earnings on August 5, 2025. The company's earnings per share (EPS) are projected to be $2.7, reflecting a 4.25% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.3 billion, up 3.5% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $10.76 per share and a revenue of $13.48 billion, signifying shifts of +11.16% and +5.15%, respectively, from the last year.
Any recent changes to analyst estimates for DaVita HealthCare should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Right now, DaVita HealthCare possesses a Zacks Rank of #3 (Hold).
Looking at its valuation, DaVita HealthCare is holding a Forward P/E ratio of 13.13. This denotes a discount relative to the industry average Forward P/E of 17.82.
One should further note that DVA currently holds a PEG ratio of 0.97. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Outpatient and Home Healthcare industry had an average PEG ratio of 1.63 as trading concluded yesterday.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 55, positioning it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DaVita HealthCare (DVA) Stock Sinks As Market Gains: What You Should Know
DaVita HealthCare (DVA - Free Report) ended the recent trading session at $139.43, demonstrating a -1.23% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.14%. On the other hand, the Dow registered a loss of 0.04%, and the technology-centric Nasdaq increased by 0.38%.
Prior to today's trading, shares of the kidney dialysis provider had gained 3.08% outpaced the Medical sector's loss of 1.94% and lagged the S&P 500's gain of 5.35%.
The investment community will be paying close attention to the earnings performance of DaVita HealthCare in its upcoming release. The company is slated to reveal its earnings on August 5, 2025. The company's earnings per share (EPS) are projected to be $2.7, reflecting a 4.25% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.3 billion, up 3.5% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $10.76 per share and a revenue of $13.48 billion, signifying shifts of +11.16% and +5.15%, respectively, from the last year.
Any recent changes to analyst estimates for DaVita HealthCare should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Right now, DaVita HealthCare possesses a Zacks Rank of #3 (Hold).
Looking at its valuation, DaVita HealthCare is holding a Forward P/E ratio of 13.13. This denotes a discount relative to the industry average Forward P/E of 17.82.
One should further note that DVA currently holds a PEG ratio of 0.97. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Outpatient and Home Healthcare industry had an average PEG ratio of 1.63 as trading concluded yesterday.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 55, positioning it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.